Danpanichkul Pojsakorn, Duangsonk Kwanjit, Kalligeros Markos, Fallon Michael B, Vuthithammee Chawinthorn, Pan Chun Wei, Saokhieo Preenapun, Derrick William, Pang Yanfang, Chen Vincent L, Kim Donghee, Singal Amit G, Yang Ju Dong, Wijarnpreecha Karn
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Aliment Pharmacol Ther. 2025 Mar;61(6):959-970. doi: 10.1111/apt.18473. Epub 2025 Jan 5.
Primary liver cancer (PLC) is projected to be the third leading cause of cancer mortality in the United States in 2040. We examine the burden of PLC in the United States, stratified by sex, state and aetiological risk factors.
Data on PLC prevalence, incidence, death and disability-adjusted life years (DALYs) were extracted from the Global Burden of Disease Study 2021. Changes in these parameters were calculated using the Joinpoint regression model.
There were 47,970 cases, 31,450 incident cases, 24,770 deaths and 576,920 DALYs from PLC in the United States. The highest prevalence (16,980), incidence (12,040), death (9840) and DALYs (213,410) from PLC were due to chronic hepatitis C virus infection. From 2000 to 2021, PLC incidences increased by 141%, and PLC deaths increased by 136%. Age-standardised incidence rates (ASIRs) and death rates (ASDRs) per 100,000 population for PLC increased, primarily driven by alcohol-related liver disease (ALD) (ASIR: annual percent change [APC]: +2.40%; ASDR: APC: +2.22%) and metabolic dysfunction-associated steatotic liver disease (MASLD) (ASIR: APC: +2.32%; ASDR: APC: +2.04%).
The burden of PLC in the United States has risen in the past two decades, driven mainly by ALD and followed by MASLD. These findings offer policymakers an accurate assessment of the PLC burden and emphasise the need for targeted risk factor mitigation, especially regarding alcohol related policy.
预计到2040年，原发性肝癌（PLC）将成为美国癌症死亡的第三大主要原因。我们按性别、州和病因风险因素对美国PLC的负担进行了研究。
从《2021年全球疾病负担研究》中提取了PLC患病率、发病率、死亡率和伤残调整生命年（DALYs）的数据。使用Joinpoint回归模型计算这些参数的变化。
美国有47,970例PLC病例、31,450例新发病例、24,770例死亡病例以及576,920个DALYs。PLC患病率（16,980）、发病率（12,040）、死亡率（9,840）和DALYs（213,410）最高的原因是慢性丙型肝炎病毒感染。从2000年到2021年，PLC发病率增加了141%，PLC死亡率增加了136%。每10万人口中PLC的年龄标准化发病率（ASIRs）和死亡率（ASDRs）有所上升，主要由酒精性肝病（ALD）（ASIR：年变化百分比[APC]：+2.40%；ASDR：APC：+2.22%）和代谢功能障碍相关脂肪性肝病（MASLD）（ASIR：APC：+2.32%；ASDR：APC：+2.04%）驱动。
在过去二十年中，美国PLC的负担有所上升，主要由ALD驱动，其次是MASLD。这些发现为政策制定者提供了对PLC负担的准确评估，并强调了减轻目标风险因素的必要性，特别是在与酒精相关的政策方面。
